RHOA and histiocytic sarcoma: In HS patients, statins may mitigate secondary injury through blood–brain barrier (BBB) stabilization via RhoA/ROCK pathway inhibition [28], reducing perihematomal edema—a key determinant of neurological deterioration [20].